Blueprint Medicines Corp - Company Profile

Powered by

All the sales intelligence you need on Blueprint Medicines Corp in one solution.

$195 $295
Register your interest Learn more
  • Save hours of research time with a comprehensive
    Sales Intelligence Solution.

  • Understand how Blueprint Medicines Corp fits into your total
    addressable market and Ideal Customer Profile.

  • Gain competitive edge with triggers that tell you
    when and how to engage with Blueprint Medicines Corp.

Back to companies

Blueprint Medicines Corp: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Blueprint Medicines Corp (Blueprint Medicines), a subsidiary of Sanofi, is a biopharmaceutical company that discovers, develops and commercializes innovative therapies for allergy, inflammation, cancer and blood disorders. The company's pipeline products include avapritinib (AYVAKIT) targets advanced systemic mastocytosis and indolent systemic mastocytosis; elenestinib for indolent systemic mastocytosis; BLU-808 treats chronic urticaria, allergic rhinoconjunctivitis, allergic asthma and mast cell activation syndrome; BLU-956 for HR+, HER2- breast cancer and CCNE1+ solid tumors. It operates through its subsidiaries in the UK, Germany, Spain, France and Italy, among others. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.

 Gain a 360-degree view of Blueprint Medicines Corp and make more informed decisions for your business Gain a 360-degree view of Blueprint Medicines Corp and make more informed decisions for your business Learn more
Headquarters United States of America
Address 45 Sidney Street, Cambridge, Massachusetts, 02139
Website www.blueprintmedicines.com
Telephone 1 617 3747580
No of Employees 682
Industry Pharmaceuticals and Healthcare
Revenue (2024) $508.8M
   
   
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Learn more

Blueprint Medicines Corp premium industry data and analytics

120+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Blueprint Medicines Corp’s relevant decision makers and contact details.

90+

Catalyst Calendar

Proactively evaluate Blueprint Medicines Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Clinical Trials

Determine Blueprint Medicines Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Pipeline Drugs

Identify which of Blueprint Medicines Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Marketed Drugs

Understand Blueprint Medicines Corp’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Blueprint Medicines Corp’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline AYVAKIT
Mast Cell Disorders:
(Avapritinib) KIT D816V:
XYZ
XYZ
XYZ
Understand Blueprint Medicines Corp portfolio and identify potential areas for collaboration Understand Blueprint Medicines Corp portfolio and identify potential areas for collaboration Learn more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2025 Ownership Changes In July, the company was acquired by Sanofi, a healthcare company.
2024 Contracts/Agreements In January, the company and VantAI entered into an agreement to improve novel targeted protein degrader therapies.
2023 Regulatory Approval In December, the company secured approval from the European Commission for AYVAKYT for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Learn more
Image for loader

Competitor Comparison

Key Parameters Blueprint Medicines Corp Eli Lilly and Co Pfizer Inc AstraZeneca Plc Novartis AG
Headquarters United States of America United States of America United States of America United Kingdom Switzerland
City Cambridge Indianapolis New York City Cambridge Basel
State/Province Massachusetts Indiana New York Cambridgeshire Basel-Stadt
No. of Employees 682 47,000 81,000 96,100 75,267
Entity Type Private Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Learn more
Executives
Name Position Board Since Age
Kathryn Haviland Chief Executive Officer; President; Director Executive Board 2022 49
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Blueprint Medicines Corp key executives to enhance your sales strategy Gain insight into Blueprint Medicines Corp key executives to enhance your sales strategy Learn more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?